Case Detail

In re CMS Cancer Drug Reimbursement Policy
(Regulatory Proceeding)
On February 10, 2004, WLF filed comments with the Centers for Medicare and Medicaid Services (CMS) in opposition to the agency's national coverage reviews of four advanced anti-cancer drugs. CMS administers the Medicare program. The agency has announced that it is considering whether to deny reimbursement for off-label uses of key drugs for colorectal cancer and non-Hodgkin's lymphoma, which kill thousands of Americans annually. WLF, joined by the Abigail Alliance and the Lorenzen Cancer Foundation, argued that off-label prescribing is vital to cancer treatment and that CMS lacks the authority to deny coverage of these medicines.
Case Status:
Awaiting CMS Action.
More Information and Downloads:

  • Welcome to the Washington Legal Foundation
  • 2009 Massachusetts Ave., NW
    Washington, DC 20036
  • info@wlf.org  |  ph. 202-588-0302
    ©2018 WLF All Rights Reserved